Chinook Therapeutics, Inc. (KDNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

20.64

+0.65

(+3.25%)

At close: 04:00PM EDT

21.58

+0.94

(+4.55%)

After hours:

04:12PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bullishpattern detected

Commodity Channel Index

View all chart patterns

Performance Outlook

Previous Close	19.99
Open	20.22
Bid	19.70 x 900
Ask	20.62 x 900
Day's Range	19.99 - 21.05
52 Week Range	10.48 - 21.11
Volume	423,265
Avg. Volume	708,417

Market Cap	1.272B
Beta (5Y Monthly)	N/A
PE Ratio (TTM)	N/A
EPS (TTM)	-1.96
Earnings Date	Nov 01, 2022 - Nov 07, 2022
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	34.63

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for KDNY

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Chinook Therapeutics, Inc.
Analyst Report: Pfizer Inc.Pfizer is a leading global developer and manufacturer of pharmaceuticals and biotech drugs. Its products include oncology and immunology drugs, treatments for rare diseases, and vaccines.
Rating
Fair Value
Economic Moat
2 days agoArgus Research

All

Simply Wall St.
Need To Know: The Consensus Just Cut Its Chinook Therapeutics, Inc. (NASDAQ:KDNY) Estimates For 2022
Today is shaping up negative for Chinook Therapeutics, Inc. ( NASDAQ:KDNY ) shareholders, with the analysts delivering...
- Earnings Beat: Benson Hill, Inc. (NYSE:BHIL) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts
  Simply Wall St.
- These Analysts Just Made A Massive Downgrade To Their Purple Innovation, Inc. (NASDAQ:PRPL) EPS Forecasts
  Simply Wall St.
GlobeNewswire
Chinook Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the quarter and six months ended June 30, 2022. “During the second quarter of 2022, we executed well on advancing our pipeline of clinical and preclinical programs for rare, severe chronic kidney diseases. We conti
GlobeNewswire
Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SEATTLE, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved a new employment inducement grant of stock options to purchase a total of 24,700 shares of common stock with a grant date of July 29, 2022 (the “Inducement Grant”) for one new employee. The